Plain-English translation of NCT06773910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new combination of two immunotherapy medicines (atigotatug and nivolumab), works better than (a standard immunotherapy) in treating early-stage small-cell lung cancer. You would receive this treatment after you've completed chemotherapy and radiation. The hope is that combining two different immunotherapy drugs may help your immune system fight the cancer more effectively.
Small-cell lung cancer is aggressive and often comes back after initial treatment. Doctors are looking for ways to improve survival by giving stronger immune-boosting therapy after chemotherapy and radiation, and this medication is designed to work in a new way against this type of cancer.
If you join this trial, you'll be randomly assigned to receive either the new combination treatment or the standard treatment through an IV infusion every 4 weeks. You'll visit the clinic regularly for infusions, blood tests, and scans to check how you're responding. The treatment continues for a set period, and you'll be followed closely by the research team to watch for any side effects or changes in your cancer.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
United States